Tagged with R

Bayer Schering Pharma Argentina The Bayer Schering merger in 2006 saw you add Argentina and Bolivia to your existing responsibilities as General Manager of Schering for Paraguay and Uruguay. What have been some of the challenges you have faced since that time? Argentina is a challenging market, and the system is very complex. This…

IMS Health Argentina It’s safe to assume that everywhere that IMS Health is established, there’s also a flourishing pharmaceutical industry. Could you give us an overview of Argentina’s IMS operations? IMS has been in Argentina for 35 years, working in information services. Two years ago, we started to offer our customers consulting services.…

Hungary With approximately $90 billion flowing into the country (according to the Hungarian Investment and Trade Agency) since it abolished its centrally planned economy and transformed into an open, pro-business economy in 1989, Hungary has been a leading destination for foreign direct investment (FDI) in Central and Eastern Europe (CEE). Together…

Sanofi Ukraine What were the factors that led to Sanofi’s decision to establish an LLC in 2009 in Ukraine, and how has it changed your operations? Most of the major foreign companies have an LLC now, for two key reasons. Firstly, it is risky to become too big and visible while continuing…

Erowlabs You have 25 years of experience in the Brazilian pharmaceutical industry, witnessing the major transformations of this market and the fast emergence of generics. Regarding your background and experience at Erowlabs, what were the main challenges you faced in order to establish the company in Brazil’s extremely competitive generics market?…

Ipsen Ukraine Ipsen has showed some very positive results worldwide in 2010 and so far this year, specifically in non-Western European markets that grew by 12% in 2010. How have the Ukrainian operations of Ipsen been faring in comparison to the global performance of the company? Let me first provide you a…

Astellas Ukraine Since the establishment of Astellas’ predecessor Brocade in Russia in 1992, what has been Astellas’ evolution in Ukraine? Astellas has been present in Ukraine for 16 years, first as Yamanouchi and then later as Astellas once the merger was complete. Since then, the company has been quite active with a…

Pharma Dynamics In 2005, when Focus Reports interviewed you, you were more towards the start up phase of Pharma Dynamics; and you have significantly grown in the market since then. What new dimension has Pharma Dynamics today in the South African pharma market, and how have you integrated the company’s growth in…

IMS Health South Africa Mr. Ehsan, you are the General Manager of IMS Africa since January 2010. What is the strategic importance of South Africa for IMS Global and for your personal country portfolio? For us, like many other multinationals (MNCs), South Africa remains a vibrant growth market. It is a country that we…

IMS Health South Africa Mrs. Reid, how would you define and describe the generic part of the South African pharmaceutical market? Linda Reid: South Africa is very much a branded generics market, and not a commodity generics market. The brand is important in South Africa and a lot of our generics are not International…

AstraZeneca Russia You have said that AstraZeneca intends to be “in Russia for Russia” and the company has recently announced a large-scale investment in this country, financing a $150Mn domestic facility in Kaluga. What are the implications of this project for AstraZeneca and why was it important for you to invest here?…

Sandoz Hungary Taking a look at the voices of the pharmaceutical industry in Hungary, we see AIPM and MAYGOSZ as the 2 key associations. And while MAGYOSZ already represents many generic players… you are in charge of a second association for generic players. Can you first explain why the need for this…